Molecular Targeting Technologies, Inc.

West Chester, PA Doing business as Mtti

UEI
Y2FNW7N1V267
CAGE
489G0
Primary NAICS
325413 In-Vitro Diagnostic Substance Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
833 Lincoln Ave #9, West Chester, PA 19380, USA
Website
mtarget.com
Founded
2011
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
This project will provide a cancer-selective, phosphatidylserine (PS)-targeted radiolabeled nanovesicle system for… HHSN261201700037C National Cancer Institute (NIH) $349,989
Sbir topic 85 to support the development of target specific molecular imaging agents in combination with existing… HHSN268201400043C National Heart Lung and Blood Institute (NIH) $222,581

Grant awards

Award Agency Obligated Awarded
Targeted radionuclide therapy for non-small cell lung cancer with LU-177 ebrgd R01CA299133 National Cancer Institute (NIH) $637,529
Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk - we propose to… R41HL167303 National Heart Lung and Blood Institute (NIH) $899,670
Instantaneous tumor spray for real-time surgical guidance - early stage ovarian cancer is typically asymptomatic… R44CA275434 National Cancer Institute (NIH) $2,998,210
Early prediction of tumor response to treatment: clinical translation of [99MTC]-duramycin R01CA226531 National Cancer Institute (NIH) $4,074,843
Sprayable, prompt color changing DYE to delineate ovarian cancer during surgery R43CA224579 National Cancer Institute (NIH) $253,411

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Celdara Medical, LLC UEI MMVKQXZUBMQ7 Lebanon, NH 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Unandup, LLC UEI KS8GMBKHNKV3 St. Louis, MO 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
Isola Therapeutics Inc. UEI M3QDM72NME75 Minneapolis, MN 339112 Surgical and Medical Instrument Manufacturing
Fox Chase Chemical Diversity Center Inc. UEI V6EQM9ABEM89 Doylestown, PA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Traverse Biotech II Inc. UEI JJUSGRQS7RM5 New York, NY —

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Molecular Targeting Technologies, Inc. (operating as Mtti) is a self-certified small disadvantaged business manufacturer and biomedical research firm based in West Chester, Pennsylvania, that develops targeted therapeutic and diagnostic agents for oncology and cardiovascular disease, operating exclusively as a federal grant recipient under the National Institutes of Health.

Mtti's federal footprint comprises 23 awards across a two-decade span, concentrated entirely in the NIH grant portfolio with no prime contract or subcontract work. The top customers by award count and combined potential value are the National Cancer Institute (5 awards, $400 thousand combined potential value) and the National Heart, Lung, and Blood Institute (2 awards, $223 thousand combined potential value), with the broader NIH accounting for 96% of awards. The National Cancer Institute anchors the active pipeline with two current grants: a $637,529 Cancer Detection and Diagnosis Research project grant (CFDA 93.394) awarded August 24, 2026, running through July 31, 2031, to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD in vertebrate animal models, and a Phase II SBIR grant awarded September 1, 2022, through August 31, 2025, in collaboration with Weill Cornell Medical School to develop a pH-sensitive near-infrared fluorogenic dye (CYPH-11) for real-time intraoperative imaging to guide ovarian cancer surgery. The National Heart, Lung, and Blood Institute funded a project grant awarded February 1, 2023, through January 31, 2025, to develop phosphatidylserine-blocking nanoparticles as an improved antithrombotic agent with reduced bleeding risk.

The vendor's activity pattern shows sparse but consistent presence: one award each in 2018, 2019, 2022, 2023, and 2026. Combined dollars obligated across all awards total $18.8 million against a combined potential value of $623 thousand, reflecting the depth of long-term funded research relationships. Mtti operates with no subcontractor role and does not compete on federal contracts, GWACs, BPAs, or agency-wide IDIQs; its entire federal engagement runs through NIH SBIR/STTR and direct project grants in life sciences research.

Quick answers

Is Molecular Targeting Technologies, Inc. registered in SAM.gov?

Yes. Molecular Targeting Technologies, Inc.'s SAM.gov registration is active through March 2, 2027.

What is Molecular Targeting Technologies, Inc.'s most recent federal award?

Molecular Targeting Technologies, Inc.'s most recent federal grant award is Targeted radionuclide therapy for non-small cell lung cancer with LU-177 ebrgd (R01CA299133), from National Cancer Institute (NIH), on August 24, 2026.

On GovTribe

See Molecular Targeting Technologies, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login